Eumentis Therapeutics
Boston
About Eumentis Therapeutics
Eumentis is a biopharmaceutical company developing treatments for neuropsychiatric conditions. Its product candidate EM-221 is an oral PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.9M
- Funding stage: Early Stage Venture
- Last round: Grant (Feb 2023)
- Website: eumentistx.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/eumentis-therapeutics-69442 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.